Hiroko Setoyama

Hiroko Setoyama

Auto-generated profile, based on publicly available information

Hiroko Setoyama

Department of Gastroenterology and Hepatology, Faculty of Life Sciences Kumamoto University Kumamoto Japan

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2026 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
HIHiroki Inada
Hiroki Inada
TTToshinori Toyota
Toshinori Toyota
HUHaruki Uojima
Haruki Uojima
EIEtsuko Iio
Etsuko Iio
TMTakao Miwa
Takao Miwa
YTYasuhito Tanaka
Yasuhito Tanaka


16 June 2026 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
HSHiroko Setoyama
Hiroko Setoyama
TWTakehisa Watanabe
Takehisa Watanabe
SMShiho Miyase
Shiho Miyase
MTMasakuni Tateyama
Masakuni Tateyama
MTMotohiko Tanaka
Motohiko Tanaka
YTYasuhito Tanaka
Yasuhito Tanaka
Background: In Japan, the hepatitis C virus (HCV) care cascade is constrained at the transition from anti‐HCV antibody screening to confirmatory HCV ribonucleic acid (HCV RNA) testing in nonspecialist departments. As HCV prevalence declines and the population ages, the two‐step antibody‐to‐RNA algorithm becomes less efficient and vulnerable to loss to follow‐up. We evaluated whether the Elecsys HCV Duo assay could function as a triage test to strengthen linkage to care. Methods: We conducted a two‐part study in Kumamoto Prefecture, Japan. First, a survey of 19 specialized institutions assessed hepatitis virus testing practices and downstream evaluation in nonspecialist departments. Second, 479 serum samples from patients undergoing HCV RNA quantification at four hospitals were prospectively evaluated using the Elecsys HCV Duo assay, with detection rates stratified by viral load. Results: Nonspecialist departments accounted for 86.6% of in‐hospital anti‐HCV testing; however, among 1416 anti‐HCV–positive individuals identified outside gastroenterology departments, only 22.7% underwent confirmatory HCV RNA testing. In the prospective evaluation of 479 samples, HCVcAg sensitivity and specificity versus HCV RNA were 62.8% and 99.8%, respectively. Detection rates increased with viral load, from 0% at ≤ 4.0 log 10 IU/mL to 16.7% at 4.1–5.5 log 10 IU/mL and 86.2% at ≥ 5.6 log 10 IU/mL. Conclusion: A vulnerability in the HCV care cascade lies at the transition from screening to confirmatory evaluation in nonspecialist settings. When implemented as a triage test within referral pathways, the Elecsys HCV Duo assay may improve linkage to specialist care while reserving HCV RNA testing for downstream confirmation.

6 July 2026 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
TTToshinori Toyota
Toshinori Toyota
SNSatoshi Narahara
Satoshi Narahara
HUHaruki Uojima
Haruki Uojima
YKYuki Kitano
Yuki Kitano
TMTakahiro Mizuta
Takahiro Mizuta
YTYasuhito Tanaka
Yasuhito Tanaka

5 June 2026 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
MNMaiko Nagaoka
Maiko Nagaoka
KNKatsuya Nagaoka
Katsuya Nagaoka
NKNaoto Kajitani
Naoto Kajitani
YYYoko Yoshimaru
Yoko Yoshimaru
TWTakehisa Watanabe
Takehisa Watanabe
YTYasuhito Tanaka
Yasuhito Tanaka